Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

Contributed by: Business Wire

Logo

Tags

Health

Medical Devices

Health Technology

Clinical Trials

Research

Science

Biotechnology

AeriSeal CONVERT II Pivotal Trial

More Like This

PR Newswire associated0

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa

PR Newswire associated0

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval

Business Wire embedded0

CroíValve Announces $16 Million Equity Financing to Fund US Early Feasibility Study of Novel Transcatheter Tricuspid Device

Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia

PR Newswire associated0

ONE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR ENDOTRONIX CORDELLA PULMONARY ARTERY SENSOR SYSTEM

ZOLL announces successful bid to acquire ventilator business from Vyaire Medical

PR Newswire associated0

PulseCath Achieves MDR CE Certification for iVAC 2L, Paving the Way for Complex High-Risk Percutaneous Coronary Interventions